| [1] |
Perez EA, Rugo HS, Vahdat LT. New developments in metastatic breast cancer: integrating recent data into clinical practice[J]. Clin Adv Hematol Oncol, 2013, 11(10 Suppl 16): 1-18, 19.
|
| [2] |
Alvarado A, Faustino-Rocha AI, Ferreira R, et al. Prognostic factors in an exercised model of chemically-induced mammary cancer[J]. Anticancer Res, 2016, 36(5): 2181-2188.
|
| [3] |
Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary[J]. Proc Natl Acad Sci U S A, 1996, 93(12): 5925-5930.
|
| [4] |
Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy[J]. Nat Rev Cancer, 2011, 11(8): 597-608.
|
| [5] |
Ma R, Karthik GM, Lovrot J, et al. Estrogen receptor beta as a therapeutic target in breast cancer stem cells[J]. J Natl Cancer Inst, 2017, 109(3): 1-14.
|
| [6] |
Hu Z, Yang L, Ning W, et al. A high-affinity subtype-selective fluorescent probe for estrogen receptor beta imaging in living cells[J]. Chem Commun (Camb), 2018, 54(31): 3887-3890.
|
| [7] |
Tarallo R, Giurato G, Bruno G, et al. The nuclear receptor ERbeta engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading[J]. Genome Biol, 2017, 18(1): 189.
|
| [8] |
Nassa G, Tarallo R, Giurato G, et al. Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor beta via microRNAs[J]. Mol Cell Proteomics, 2014, 13(4): 1076-1090.
|
| [9] |
Marotti JD, Collins LC, Hu R, et al. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study[J]. Mod Pathol, 2010, 23(2): 197-204.
|
| [10] |
Guo L, Meng J, Yilamu D, et al. Significance of ERbeta expression in different molecular subtypes of breast cancer[J]. Diagn Pathol, 2014, 9: 20.
|
| [11] |
Guo L, Zhang Y, Zhang W, et al. Correlation between estrogen receptor beta expression and the curative effect of endocrine therapy in breast cancer patients[J]. Exp Ther Med, 2014, 7(6): 1568-1572.
|
| [12] |
Shanle EK, Zhao Z, Hawse J, et al. Research resource: global identification of estrogen receptor beta target genes in triple negative breast cancer cells[J]. Mol Endocrinol, 2013, 27(10): 1762-1775.
|
| [13] |
Skliris GP, Munot K, Bell SM, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model[J]. J Pathol, 2003, 201(2): 213-220.
|
| [14] |
Tan W, Li Q, Chen K, et al. Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis[J]. Oncotarget, 2016, 7(9): 10373-10385.
|
| [15] |
Bado I, Nikolos F, Rajapaksa G, et al. Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis[J]. Breast Cancer Res, 2017, 19(1): 79.
|
| [16] |
Nair HB, Perla RP, Kirma NB, et al. Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice[J]. Horm Cancer, 2012, 3(1-2): 26-36.
|
| [17] |
Hartman J, Strom A, Gustafsson JA. Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications[J]. Steroids, 2009, 74(8): 635-641.
|
| [18] |
Zhao L, Huang S, Mei S, et al. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis[J]. Proc Natl Acad Sci U S A, 2018, 115(16): E3673-3681.
|
| [19] |
Bowers LW, Wiese M, Brenner AJ, et al. Obesity suppresses estrogen receptor beta expression in breast cancer cells via a HER2-mediated pathway[J]. PLoS One, 2015, 10(12): e145452.
|
| [20] |
Jonsson P, Katchy A, Williams C. Support of a bi-faceted role of estrogen receptor beta (ERbeta) in ERalpha-positive breast cancer cells[J]. Endocr Relat Cancer, 2014, 21(2): 143-160.
|
| [21] |
Liu J, Guo H, Mao K, et al. Impact of estrogen receptor-beta expression on breast cancer prognosis: a meta-analysis[J]. Breast Cancer Res Treat, 2016, 156(1): 149-162.
|
| [22] |
Elebro K, Borgquist S, Rosendahl AH, et al. High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients-results from a population-based breast cancer cohort[J]. Clin Cancer Res, 2017, 23(3): 766-777.
|
| [23] |
Speirs V, Green AR, Hughes TA, et al. Clinical importance of estrogen receptor beta isoforms in breast cancer[J]. J Clin Oncol, 2008, 26(35): 5825.
|
| [24] |
Mandusic V, Dimitrijevic B, Nikolic-Vukosavljevic D, et al. Different associations of estrogen receptor beta isoforms, ERbeta1 and ERbeta2, expression levels with tumor size and survival in early- and late-onset breast cancer[J]. Cancer Lett, 2012, 321(1): 73-79.
|
| [25] |
Bialesova L, Xu L, Gustafsson JA, et al. Estrogen receptor beta2 induces proliferation and invasiveness of triple negative breast cancer cells: association with regulation of PHD3 and HIF-1alpha[J]. Oncotarget, 2017, 8(44): 76622-76633.
|
| [26] |
Chantzi NI, Tiniakos DG, Palaiologou M, et al. Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma[J]. J Cancer Res Clin Oncol, 2013, 139(9): 1489-1498.
|
| [27] |
Shaaban AM, Green AR, Karthik S, et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients[J]. Clin Cancer Res, 2008, 14(16): 5228-5235.
|
| [28] |
Lee MT, Ho SM, Tarapore P, et al. Estrogen receptor beta isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12[J]. Neoplasia, 2013, 15(11): 1262-1271.
|
| [29] |
Reese JM, Bruinsma ES, Monroe DG, et al. ERbeta inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer[J]. Oncotarget, 2017, 8(57): 96506-96521.
|
| [30] |
Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy[J]. J Clin Oncol, 2008, 26(22): 3727-3734.
|
| [31] |
Sakamoto G, Honma N. Estrogen receptor-beta status influences clinical outcome of triple-negative breast cancer[J]. Breast Cancer, 2009, 16(4): 281-282.
|
| [32] |
Wang J, Zhang C, Chen K, et al. ERbeta1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2015, 152(2): 255-269.
|
| [33] |
Faria M, Karami S, Granados-Principal S, et al. The ERbeta4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERbeta variants ERbeta2 and ERbeta5 increase aggressiveness of TNBC by regulation of hypoxic signaling[J]. Oncotarget, 2018, 9(15): 12201-12211.
|
| [34] |
Mcnamara KM, Oguro S, Omata F, et al. The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer[J]. Breast Cancer Res Treat, 2017, 161(2): 213-227.
|
| [35] |
Hinsche O, Girgert R, Emons G, et al. Estrogen receptor beta selective agonists reduce invasiveness of triple-negative breast cancer cells[J]. Int J Oncol,2015,46(2): 878-884.
|
| [36] |
Grober OM, Mutarelli M, Giurato G, et al. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation[J]. BMC Genomics, 2011, 12: 36.
|
| [37] |
Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family[J]. Am J Surg Pathol, 2008, 32(4): 513-523.
|
| [38] |
Dalasanur NL, Adhikari R, Singhal J, et al. Translational opportunities for broad-spectrum natural phytochemicals and targeted agent combinations in breast cancer[J]. Int J Cancer, 2018, 142(4): 658-670.
|
| [39] |
Wolff M, Kosyna FK, Dunst J, et al. Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells[J]. Arch Biochem Biophys, 2017, 613: 23-30.
|
| [40] |
Sastre-Serra J, Nadal-Serrano M, Pons DG, et al. The oxidative stress in breast tumors of postmenopausal women is ERalpha/ERbeta ratio dependent[J]. Free Radic Biol Med, 2013, 61: 11-17.
|
| [41] |
Li HT, Liu HH, Yang YX, et al. Therapeutic effects of a traditional Chinese medicine formula plus tamoxifen vs. tamoxifen for the treatment of mammary gland hyperplasia: a meta-analysis of randomized trials[J]. Front Pharmacol, 2018, 9: 45.
|
| [42] |
Madeira M, Mattar A, Logullo AF, et al. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer[J]. BMC Cancer, 2013, 13: 425.
|
| [43] |
Guo L, Zhang YU, Yilamu D, et al. ERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients[J]. Oncol Lett, 2016, 11(2): 1531-1536.
|
| [44] |
Gschwantler-Kaulich D, Fink-Retter A, Czerwenka K, et al. Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases[J]. Tumour Biol, 2011, 32(3): 501-508.
|
| [45] |
Motomura K, Ishitobi M, Komoike Y, et al. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors[J]. Oncology, 2010, 79(1-2): 55-61.
|
| [46] |
Mishra AK, Abrahamsson A, Dabrosin C. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ[J]. Oncotarget, 2016, 7(35): 56876-56888.
|